Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Various

Liver disease, pulmonary fibrosis

Integrin aV (CD51)

Studies in mice suggest a small molecule inhibitor of CD51 could help treat fibrosis. In mouse models of liver, lung and kidney fibrosis, Cd51 knockout in myofibroblasts prevented fibrosis. In mouse models of fibrosis, a small molecule inhibitor of Cd51 decreased fibrosis progression in liver and lung compared with an inactive enantiomer. Next steps include identifying CD51 dimerization partners in profibrotic integrin complexes and assessing cellular and transcriptional changes resulting from CD51 inhibition.
The CD51 inhibitor was developed by new company Antegrin Therapeutics LLC (see Targeting fibrotic integrin, page 1).

SciBX 6(46); doi:10.1038/scibx.2013.1329
Published online Dec. 5, 2013

Patent application for CD51 inhibitor and related inhibitors filed by Antegrin Therapeutics; patent application filed by the University of California, San Francisco covering identification of CD51-containing integrins; available for licensing

Henderson, N.C. et al. Nat. Med.; published online Nov. 10, 2013;
doi:10.1038/nm.3282
Contact: Dean Sheppard, University of California, San Francisco, Calif.
e-mail:

dean.sheppard@ucsf.edu
Contact: Neil C. Henderson,
The University of Edinburgh,
Edinburgh, U.K.
e-mail:

henderson@ed.ac.uk